[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100566682":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":30,"responsibleParty":45,"collaborators":11,"id":47,"slug":11,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":11,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":11,"enrollmentInfo":55,"targetDuration":11,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":11,"overallStatus":32,"whyStopped":11,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Jiangsu vcare pharmaceutical technology co., LTD","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"VC004 Capsules","EXPERIMENTAL",null,[13],"Drug: VC004 Capsules",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"DRUG","VC004 Capsules BID",[9],[20],{"name":21,"affiliation":22,"role":23},"yuankai Shi","Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":11,"email":29},"xiaojuan Lai","CONTACT","15358160458","lai_xiaojuan@vcarepharmatech.com",[31],{"facility":22,"status":32,"city":33,"state":34,"zip":11,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"RECRUITING","Beijing","Beijing Municipality","China",{"type":37,"coordinates":38},"Point",[39,40],116.39723,39.9075,{"lat":40,"lon":39},[43],{"name":44,"role":27,"phone":11,"phoneExt":11,"email":11},"Ning Li",{"type":46,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100566682",false,"NCT06658353","Phase III Clinical Study of VC004 in Patients With Localized Advanced\u002F Metastatic Solid Tumors","Single-arm, Open, Multi-center Phase III Clinical Study to Assess the Safety and Effectiveness of VC004 in Patients With Localized Advanced\u002F Metastatic Solid Tumors","Inclusion Criteria:\n\n* All subjects or legal representatives are willing and able to sign ICF approved by the ethics committee before starting any screening procedures；\n* Male or female, age ≥12 years old;\n\nExclusion Criteria:\n\n* Patients have undergone major surgery within 4 weeks prior to the first dose or are expected to undergo major surgery during the trial (excluding vascular access establishment procedures, biopsy procedures);\n* Adverse reactions caused by previous treatment have not recovered to ≤1 grade (evaluated by the investigator);\n* Patients had been treated with a strong CYP3A inhibitor or inducer within 7 days prior to the first administration of the study drug.","ALL","12 Years",{"count":56,"type":57},54,"ESTIMATED","INTERVENTIONAL",[60],"PHASE3","This Study is a single arm, open label, multicenter phase III clinical trial to evaluate the safety and efficacy of VC004 in patients with locally advanced\u002Fmetastatic solid tumors.",[63],"Locally Advanced Solid Tumor","2025-03-18",{"date":66,"type":67},"2025-03-20","ACTUAL",{"date":69,"type":67},"2025-03-17",{"date":71,"type":57},"2026-12-30",{"name":5,"class":6},1]